CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRIS…
Biotechnology
CH, Zug [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about CRISPR Therapeutics AG's gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | - | -2.220 | - | 5 | - | -175 | - | -1 | - | -2 | - | 397 |
| 2017 | -1.8900 | -2.378 | 5 | 11 | -23 | -188 | -25 | -4 | -68 | -4 | 31 | 926 |
| 2018 | -1.7100 | -3.281 | 40 | 6 | -68 | -127 | -61 | -123 | -64 | -122 | 35 | 481 |
| 2019 | -3.4400 | 0.008 | 3 | 257 | -164 | 548 | -158 | -101 | -158 | -106 | 48 | 134 |
| 2020 | 1.2300 | -5.022 | 289 | 2 | 66 | -282 | 46 | -274 | -132 | -287 | 63 | 184 |
| 2021 | -5.2900 | 4.883 | 0.54 | 903 | -348 | 338 | -345 | 357 | -623 | 334 | 88 | 99 |
| 2022 | 4.9700 | -9.088 | 913 | 6 | 377 | -603 | 373 | -573 | 355 | -604 | 102 | 488 |
| 2023 | -8.3600 | -2.917 | 0.44 | 293 | -650 | -265 | -673 | -587 | -673 | -619 | 102 | 103 |
| 2024 | -1.9400 | -5.623 | 370 | 44 | -153 | -445 | -202 | -17 | -222 | -18 | 76 | 3,542 |
| 2025 | - | -4.914 | - | 240 | - | -492 | - | -94 | - | -99 | - | 19,112 |
| 2026 | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |